LICENSE AGREEMENTLicense Agreement • March 15th, 2016 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This License Agreement (this “Agreement”), dated as of January 25, 2016 (the “Effective Date”), is made by and between Agenus Inc., a Delaware corporation with offices at 3 Forbes Rd, Lexington, MA 02421 (“Parent”) and its wholly owned subsidiary, 4-Antibody AG, a corporation organized under the laws of Switzerland with an office at Hochbergerstrasse 60C, CH-4057 Basel, Switzerland (“4AB,” and together with the Parent, “Agenus”), and the Ludwig Institute for Cancer Research Ltd., a non-profit corporation organized under the laws of Switzerland with its registered office at Stadelhoferstrasse 22, 8001 Zurich, Switzerland and an office at 666 Third Avenue, New York, New York 10017, USA (“LICR”). Each of Agenus and LICR may be referred to in this Agreement individually as a “Party” and, collectively, as the “Parties”.
license agreementLicense Agreement • March 15th, 2016 • Agenus Inc • Biological products, (no disgnostic substances)
This License Agreement (as amended, hereinafter “Agreement”) is made this 19th day of March, 2013 (“Effective Date”) by and between the University of Virginia Patent Foundation d/b/a University of Virginia Licensing and Ventures Group, a Virginia non-profit corporation, having a principal place of business at 250 W. Main Street, Suite 300, Charlottesville, VA 22902 (“UVA LVG”) and PhosImmune, Inc., having a principal place of business at PhosImmune, Inc., c/o Fanelli Haag & Kilger PLLC, 1909 K Street, N.W., Suite 1120, Washington, D.C. 20006 (“Licensee”), (each a “Party” or collectively the “Parties”).
